Peginterferon beta-1a reduces disability worsening in relapsing–remitting multiple sclerosis: 2-year results from ADVANCE

BACKGROUND: In the pivotal phase III 2-year ADVANCE study, subcutaneous peginterferon beta-1a 125 mcg every 2 weeks demonstrated significant improvements in clinical outcomes, including disability endpoints, in patients with relapsing–remitting multiple sclerosis (RRMS). Here, we aim to further eval...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Neurol Disord
Egile Nagusiak: Newsome, Scott D., Kieseier, Bernd C., Liu, Shifang, You, Xiaojun, Kinter, Elizabeth, Hung, Serena, Sperling, Bjoern
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2016
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400156/
https://ncbi.nlm.nih.gov/pubmed/28450894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285616676065
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak